Gentronix is a CRO that provides toxicology tests required by regulators for companies developing new chemical and pharmaceutical products. Led by Managing Director Matt Tate, the firm specialises in genetic, skin and ocular toxicology services. It recently acquired the Big Blue® transgenic mutation assay from Merck KGaA, one of only three tests worldwide used for final assessment of potential mutagenicity. The company employs over 40 staff, including expert toxicologists, and serves clients such as top-five pharmaceutical, chemical and agrochemical organisations. Gentronix plans to use the new funding to onboard and deliver the Big Blue® service and to expand its genetic, skin and ocular toxicology offerings. Gentronix is a UK-based contract research firm offering toxicology testing services to major global brands across pharmaceuticals, agrochemicals, cosmetics, personal care and consumer products. The company supports hazard and safety assessments from early-stage discovery through regulatory submission and approval. Services are delivered by an expert scientific team that emphasizes minimal use of test substances and responsive timeframes. Led by CEO Matt Tate, Gentronix received £750k in third funding from the Northern Venture Capital Trust Funds managed by Mercia. The company intends to use the proceeds to create 30 new jobs and to expand its capabilities and services. The article does not detail the financing instrument beyond the £750k amount.

Total raised

$2M

Funding rounds

2

Latest round

Equity

Latest activity

Nov 2021